Fierce Pharma2d
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
GlobalData on MSN2d
FDA grants accelerated approval to Novartis’ Vanrafia for IgAN
The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.
Medical Dialogues22h
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
PharmExec1d
FDA Approves Novartis’ Vanrafia for Primary Immunoglobulin A Nephropathy
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
Managed Healthcare Executive2d
FDA Grants Accelerated Approval to Vanrafia for IgAN, a Rare Kidney Disease
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
MPR1d
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
PMLive1d
Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
The Pharma Letter2d
FDA accelerated approval for Novartis’ Vanrafia
Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...
Medical Dialogues2d
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.